Peripheral Neuropathy Induced by Microtubule-Stabilizing Agents

American Society of Clinical Oncology (ASCO) - Tập 24 Số 10 - Trang 1633-1642 - 2006
James J. Lee1, Sandra M. Swain2
1Breast Cancer Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20889-5015, USA.
2From the Breast Cancer Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD

Tóm tắt

Microtubule-stabilizing agents (MTSAs), including the taxanes and epothilones, are effective chemotherapeutic agents for the treatment of many cancers. Neuropathy is a major adverse effect of MTSA-based chemotherapy, with severe peripheral neuropathy (grade 3 or 4) occurring in as many as 30% of patients treated with a MTSA. MTSA-induced neuropathy usually resolves gradually after cessation of the treatment. The most reliable method to accurately assess MTSA-induced neuropathy is by clinical evaluation, although additional techniques are being developed and evaluated. Among MTSA-induced neuropathy, the most extensively studied is that induced by taxanes; such a neuropathy usually presents as sensory neuropathy and is more common with paclitaxel than docetaxel. The incidence of MTSA-induced neuropathy seems to depend on the MTSA dose per treatment cycle, the schedule of treatment, and the duration of the infusion. Although there have been several small clinical trials with neuroprotective agents, early recognition and supportive care are the best approaches for prevention and management of MTSA-induced neuropathy. In the future, research should focus on elucidating the mechanism of MTSA-induced neuropathy, developing reliable in vivo and in vitro preclinical models to study MTSA-induced neuropathy, developing a more reliable grading system for MTSA-induced neuropathy, developing more reliable methods for evaluating MTSA-induced neuropathy, and evaluating the efficacy of potential neuroprotective agents in clinical trials.

Từ khóa


Tài liệu tham khảo

10.1038/277665a0

10.1091/mbc.10.4.947

10.1200/JCO.2004.00.6148

O'Shaughnessy J, Blum J, Sandbach J, et al: Weekly nanoparticle albumin paclitaxel (Abraxane) results in long-term disease control in patients with taxane-refractory metastatic breast cancer . 27th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-11, 2004 (abstr 1070)

Ibrahim NK, Samuels B, Page R, et al: Nanoparticle paclitaxel (ABI-007) in metastatic breast cancer (MBC): Efficacy and evidence of dose-dependent activity in two multicenter phase II studies. Proc Am Soc Clin Oncol 21:53a,2002, (abstr 209)

10.1200/JCO.2005.04.937

10.1200/JCO.2005.03.8844

Von Hoff DD: The taxoids: Same roots, different drugs. Semin Oncol 24:S13,1997-3–S13-10,

10.1200/jco.2004.22.14_suppl.2015

10.1200/jco.2004.22.14_suppl.2061

10.1200/jco.2004.22.14_suppl.513

10.1200/JCO.1999.17.11.3403

Ravdin P, Erban J, Overmoyer B, et al: Phase III comparison of docetaxel (D) and paclitaxel (P) in patients with metastatic breast cancer (MBC). Eur J Cancer 1:S201,2003, (suppl 1, abstr 670)

10.1200/JCO.2000.18.4.724

Mouridsen H, Harvey V, Semiglazov V, et al: Phase III study of docetaxel 100 versus 75 versus 60 mg/m2 as second line chemotherapy in advanced breast cancer . 25th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 11-14, 2002 (abstr 327)

10.1200/JCO.1999.17.8.2341

10.1200/JCO.1999.17.5.1413

10.1097/00001813-200004000-00004

Blum JL, Savin MA, Edelman G, et al: Long term disease control in taxane-refractory metastatic breast cancer treated with nab paclitaxel. J Clin Oncol 22:13s,2004, (suppl 14; abstr 543)

10.1200/JCO.2005.10.024

Zhuang SH, Menefee M, Kotz H, et al: A phase II clinical trial of BMS-247550 (ixabepilone), a microtubule-stabilizing agent in renal cell cancer. J Clin Oncol 22:394s,2004, (suppl 14; abstr 4550)

10.1200/JCO.2005.09.042

Thomas E, Tabernero J, Fornier M, et al: A phase II study of the epothilone B analog BMS-247550 in patients (pts) with taxane-resistant metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 22:8,2003, (abstr 30)

Roche HH, Cure H, Bunnell C, et al: A phase II study of epothilone analog BMS-247550 in patients (pts) with metastatic breast cancer (MBC) previously treated with an anthracycline. Proc Am Soc Clin Oncol 22:18,2003, (abstr 69)

10.1200/JCO.2005.02.4448

10.1093/annonc/mdh236

Hussain A, Dipaola RS, Baron AD, et al: A phase IIa trial of weekly EPO906 in patients with hormone-refractory prostate cancer (HPRC). J Clin Oncol 22:397s,2004, (suppl 14; abstr 4563)

Piro LD, Rosen LS, Parson M, et al: KOS-862 (epothilone D): A comparison of two schedules in patients with advanced malignancies. Proc Am Soc Clin Oncol 22:135,2003, (abstr 539)

10.1200/JCO.2005.05.304

Overmoyer B, Waintraub S, Kaufman PA, et al: Phase II trial of KOS-862 (epothilone D) in anthracycline and taxane pretreated metastatic breast cancer. J Clin Oncol 23:72s,2005, (suppl 16; abstr 778)

Mekhail T, Chung C, Holden S, et al: Phase I trial of novel epothilone B analog BMS-310705 IV q 21 days. Proc Am Soc Clin Oncol 22:129,2003, (abstr 515)

10.1158/1078-0432.CCR-04-1655

Jacobson SD, Loprinzi CL, Sloan JA, et al: Glutamine does not prevent paclitaxel-associated myalgias and arthralgias. J Support Oncol 1:274,2003-278,

Vahdat L, Papadopoulos K, Lange D, et al: Reduction of paclitaxel-induced peripheral neuropathy with glutamine. Clin Cancer Res 7:1192,2001-1197,

10.1158/1078-0432.CCR-0772-03

10.1016/j.ygyno.2004.11.052

10.1055/s-2008-1040857

10.1007/s004410050019

10.1016/S0168-0102(99)00074-7

10.1007/BF01148489

Cavaletti G, Cavalletti E, Montaguti P, et al: Effect on the peripheral nervous system of the short-term intravenous administration of paclitaxel in the rat. Neurotoxicology 18:137,1997-145,

10.1001/archneur.1994.00540190110024

Wiernik PH, Schwartz EL, Strauman JJ, et al: Phase I clinical and pharmacokinetic study of Taxol. Cancer Res 47:2486,1987-2493,

10.1200/JCO.1996.14.6.1858

10.1158/1078-0432.CCR-05-0298

10.1200/JCO.1994.12.12.2654

10.1200/JCO.2005.02.027

Lee JJ, Low JA, Croarkin E, et al: Evaluation of neuropathy in breast cancer patients treated with ixabepilone. J Clin Oncol 23:42s,2005, (suppl 16; abstr 657)

Rowinsky EK, Eisenhauer EA, Chaudhry V, et al: Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 20:1,1993-15,

Rowinsky EK, Chaudhry V, Cornblath DR, et al: Neurotoxicity of Taxol. J Natl Cancer Inst Monogr 15:107,1993-115,

10.1006/gyno.1996.0090

10.1093/annonc/mdh395

10.1002/ana.410350310

10.1002/cncr.11375

10.1007/s11910-003-0043-8

10.1002/ana.10039

10.1002/ana.10300

10.1006/nbdi.2000.0334

10.1046/j.1365-2141.2003.04430.x

10.1200/JCO.1995.13.12.2886

10.1212/WNL.46.1.108

10.1093/jnci/83.24.1797-a

10.1212/WNL.46.1.104

10.1093/jnci/85.8.676

10.1046/j.1525-1438.1999.99046.x

10.1212/WNL.47.1.115

10.1046/j.1525-1438.1995.05030161.x

10.1093/oxfordjournals.annonc.a059220

10.1200/JCO.1995.13.12.2879

10.1097/00000421-198212000-00014

10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6

10.1023/A:1008345613594

10.2337/diacare.12.4.270

10.1023/A:1008344507482

10.1093/jnci/85.14.1138

10.1002/cncr.11578

10.1016/S0959-8049(00)00369-5

10.1200/JCO.2005.10.522

10.1200/JCO.2005.08.147

10.1093/jnci/85.5.365

10.1200/JCO.2003.02.075

10.1016/j.ejca.2005.02.012

10.1097/00004691-199803000-00005

10.1023/A:1005805907311

10.1016/j.jdiacomp.2003.12.006

10.1159/000052132

10.2337/diacare.24.2.250

Jebsen RH, Taylor N, Trieschmann RB, et al: An objective and standardized test of hand function. Arch Phys Med Rehabil 50:311,1969-319,

10.1097/00007611-199109000-00013

Meneilly GS, Cheung E, Tessier D, et al: The effect of improved glycemic control on cognitive functions in the elderly patient with diabetes. J Gerontol 48:M117,1993-M121,

Trites R: Neuropsychological Test Manual . Ottawa, Ontario, Canada, Royal Ottawa Hospital, 1977

10.2466/pms.1993.76.3c.1219

Low J, Croarkin E, Parks R, et al: Assessment of neurotoxicity in patients receiving BMS-247550 for metastatic breast cancer . 26th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 3-6, 2003 (abstr 358)

10.1212/WNL.39.3.368

10.1007/s004010051132

Davidson NG: Single-agent paclitaxel as first-line treatment of metastatic breast cancer: The British experience. Semin Oncol 23:6,1996-10,

10.1200/JCO.1998.16.10.3353

10.1200/JCO.2004.99.298

10.1200/JCO.1999.17.1.434

10.1007/s00520-005-0782-y

10.1093/annonc/mdg301

10.1200/JCO.2003.02.086

10.1200/JCO.2004.06.132

10.1200/JCO.2003.11.005

10.1200/JCO.1999.17.10.3038

Socinski MA, Tynan M, Natoli S, et al: Phase II trial of paclitaxel (P), carboplatin (C) and amifostine in stage IV non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 18,1999, (abstr 2015)

Robinson J, Akerley W, Safran H, et al: High dose weekly paclitaxel (P) and amifostine (as a neuroprotectant) for advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 18,1999, (abstr 2337)

Takeda K, Negoro S, Matsui K, et al: Phase I safety and pharmacokinetic trial of BNP7787 in patients receiving cisplatin (CDDP) and paclitaxel (PTX) for advanced non-small cell lung cancer (NSCLC): An Osaka phase I study group trial. Proc Am Soc Clin Oncol 21:114a,2002, (abstr 453)

Davis ID, Kiers L, Quinn M, et al: A randomized, double-blinded, placebo-controlled phase II trial to determine the safety and efficacy of AM424 (emfilermin, rhLIF) in the prevention of chemotherapy-induced peripheral neuropathy (CIPN). Proc Am Soc Clin Oncol 22:740,2003, (abstr 2976)

10.1016/j.ejca.2005.04.028

10.1177/030089160509100206

10.1016/j.clon.2004.11.014

10.1212/01.WNL.0000148609.35718.7D

10.1517/14656566.2.3.479

Hilpert F, Staehle A, Oliver T, et al: Neuroprotection with amifostine in 1st-line treatment of advanced ovarian cancer with carboplatin/taxane-based chemotherapy: A double-blind, placebo-controlled, randomized phase II-study of the AGO Ovarian Cancer Study Group. Proc Am Soc Clin Oncol 22:448,2003, (abstr 1801)

10.1200/JCO.1999.17.10.3333

10.1200/JCO.2002.04.178

Pendyala L, Schwartz G, Smith P, et al: Modulation of plasma thiols and mixed disulfides by BNP7787 in patients receiving paclitaxel/cisplatin therapy. Cancer Chemother Pharmacol 51:376,2003-384,

10.1007/s00280-003-0653-5

10.1038/sj.bjc.6602553

10.1023/A:1006124917643

10.1023/A:1008407014084

Bove L, Picardo M, Maresca V, et al: A pilot study on the relation between cisplatin neuropathy and vitamin E. J Exp Clin Cancer Res 20:277,2001-280,

10.7326/0003-4819-142-1-200501040-00110

Thông tin
Thông tin xuất bản

American Society of Clinical Oncology (ASCO)

Tập 24 Số 10

1633-1642

Thông tin tác giả